Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14951 - 14975 of 15433 in total
OMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.
Investigational
OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).
Investigational
SJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and Secondary Myelodysplastic Syndromes, among others.
Investigational
Matched Description: … Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and
Clinafloxacin is a fluoroquinolone antibacterial currently under research. It has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.
Investigational
Matched Description: … However, its approval and release have been halted due to the presence of serious side effects. …
Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery).
Investigational
Matched Iupac: … amino-1-[(2S)-2-{[(1S)-1-carbamoyl-2-methylpropyl]carbamoyl}pyrrolidin-1-yl]-1-oxohexan-2-yl]carbamoyl}methyl
Matched Description: … Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple …
AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection.
Investigational
Matched Description: … AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to …
Relacorilant is under investigation in clinical trial NCT02804750 (Study to Evaluate CORT125134 in Patients With Cushing's Syndrome).
Investigational
Matched Iupac: … 2-[(4aR)-1-(4-fluorophenyl)-6-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-1H,4H,4aH,5H,6H,7H,8H-pyrido[3,4-f …
Hetrombopag is under investigation in clinical trial NCT03976882 (Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Subjects With Malignancy.).
Investigational
Matched Iupac: … 5-(2-hydroxy-3-{2-[(4Z)-3-methyl-5-oxo-1-(5,6,7,8-tetrahydronaphthalen-2-yl)-4,5-dihydro-1H-pyrazol-4 …
Investigational
Matched Iupac: … 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N …
PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders. It is being developed by Schering-Plough and Pharmacopeia. Little information has been released about PS386113.
Investigational
Matched Description: … It is being developed by Schering-Plough and Pharmacopeia. …
Mimopezil is an acetylcholinesterase (AChE) inhibitor that has demonstrated potential use in the treatment of Alzheimer's disease. Mimopezil is a pro-drug that is rapidly absorbed and converted into huperzine A.
Investigational
Matched Iupac: … (1R,9R,13E)-1-[(E)-[(5-chloro-2-hydroxy-3-methoxyphenyl)methylidene]amino]-13-ethylidene-11-methyl-6- …
Matched Description: … Mimopezil is a pro-drug that is rapidly absorbed and converted into huperzine A. …
AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's cancer cells.
Investigational
Matched Description: … immune response characteristics, that is designed to stimulate the patient's immune system to target and
Methamidophos is under investigation in clinical trial NCT03223753 (Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission).
Investigational
Matched Description: … trial NCT03223753 (Web-Based Physical Activity Intervention in Improving Long Term Health in Children and
Fulacimstat is under investigation in clinical trial NCT02452515 (A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction).
Investigational
Matched Iupac: … 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)-4-(trifluoromethyl)-2,3-dihydro- …
Matched Description: … under investigation in clinical trial NCT02452515 (A Single-blind Pilot Study to Investigate Safety and
MK-2748 is under investigation in clinical trial NCT01593735 (A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)).
Investigational
Matched Description: … is under investigation in clinical trial NCT01593735 (A Multiple Dose Study to Evaluate the Safety and
Tulrampator is under investigation in clinical trial NCT02626572 (Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms).
Investigational
Matched Description: … Tulrampator is under investigation in clinical trial NCT02626572 (Efficacy and Safety of 3 Doses of S47445 …
Experimental
Experimental
Thienylfentanyl is a fentanyl analog analgesic that was sold on the black market in the 1980s until the Federal Analog Act scheduled drugs based on structural similarity rather than scheduling drugs individually. Thienylfentanyl has a similar synthesis pathway to fentanyl except 2-(2-bromoethyl)thiophene is substituted for phenethyl bromide.
Illicit
ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU). CoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer.
Investigational
Matched Description: … ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce …
Displaying drugs 14951 - 14975 of 15433 in total